Before joining Biomay, May Guo served as Chief Commercial Officer at Synthgene/Areterna, an mRNA technology company, and held senior leadership roles including Vice President at ReciBioPharm and Director of Business Development at TriLink BioTechnologies. She holds a bachelor’s degree in chemistry from Peking University and an MBA from Georgetown University
“We are thrilled to welcome May Guo to our executive team,” said Hans Huber, CEO of Biomay. “Her deep industry knowledge and extensive network will be instrumental in driving our business growth and expanding our global footprint. May is a recognized opinion leader in the mRNA/LNP field. At Biomay, she will strengthen our leadership team and drive innovation. It’s a pleasure having her on board.”
“I am impressed by Biomay’s track record and the company´s state-of-the-art manufacturing facilities and quality systems,” said May Guo. “As an FDA-inspected manufacturer, we are committed to delivering pDNA, mRNA, and recombinant protein products of the highest quality, helping clients succeed in their clinical programs.”
About Biomay
Biomay is a fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, Biomay has specialized in the expression of recombinant proteins in E. coli from its inception. Today, the company provides cGMP services for the manufacturing of messenger RNA (mRNA), circular plasmid DNA, linear IVT-template DNA, and therapeutic recombinant proteins.
Biomay operates a dedicated mRNA Competence Center for cGMP manufacturing and QC testing of mRNA drug substance and drug product (clinical and commercial). Services include process and analytical development, cell banking, R&D material supply, cGMP manufacturing, lipid nanoparticle (LNP) formulation, and aseptic filling. Biomay’s facilities are inspected by the US FDA.
Contact
Biomay AG
P: +43 1 / 7966296-100
E: request@biomay.com